Abstract
IntroductionTo identify patient preference drivers related to the management of wet age-related macular degeneration (wet AMD).MethodsIn this cross-sectional study, a self-explicated ‘conjoint analysis’ survey was administered online to eligible patients with wet AMD (receiving anti-vascular endothelial growth factor [VEGF] treatment for at least 12 months) from the USA, Canada, UK, France, Spain, Germany, Italy, Japan, Taiwan, and Australia. The survey consisted of six domains with 21 attributes, which were selected on the basis of a literature review, social media listening, and tele-interviews/discussions with patients, clinical experts, and patient groups. Utility and relative importance scores were generated for each attribute and utility difference significance testing was performed using ‘unequal variances t tests’. The Patient Activation Measure (PAM-13) questionnaire was administered to assess patients’ knowledge, skill, and confidence in self-management.ResultsA total of 466 patients (mean age, 68 years; women, 54%; binocular wet AMD, 28%) with an average anti-VEGF treatment duration of 3.9 years completed the survey. The most important preference domains were ‘treatment effects on vision’ (non-significant) and ‘vision-related symptom burdens’ (p < 0.001), followed by ‘treatment risk’ (p < 0.05), ‘impact on daily activities’ (p < 0.05), ‘burden of clinic/hospital visits’ (p < 0.001), and ‘impact on psychological well-being’. The five most important attributes in order of importance were clarity of vision, treatment effect on symptoms, quality of vision, time to treatment effect, and time to re-administration. The two most important attributes globally were also in the top three attributes across countries. The majority of participants in the study were level 3 or level 4 of the PAM-13 questionnaire.ConclusionsThis study identified the most important disease and treatment attributes to patients using patient-centred methods. The data showed the degree of harmonization of preferences across geographies and that participants actively adopt behaviours required for improved treatment outcomes. The identified preference drivers may inform future clinical development.Supplementary InformationThe online version contains supplementary material available at 10.1007/s12325-022-02248-5.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.